Current studentsExisting staffContact us
 

Targeting peripheral blood pro-inflammatory CD28null T cells and natural killer T-like cells by inhibiting CD137 expression: Possible relevance to treatment of bronchiolitis obliterans syndrome

Simple item page
dc.contributor.authorHodge, G.
dc.contributor.authorHodge, S.
dc.contributor.authorReynolds, P.
dc.contributor.authorHolmes, M.
dc.date.issued2013
dc.description.abstractBACKGROUND: We have shown that bronchiolitis obliterans syndrome (BOS) is associated with attenuated suppression of pro-inflammatory cytokines and granzyme B by steroid-resistant peripheral blood CD28nullCD137+ T cells and natural killer T (NKT)-like cells. We hypothesized that we could target these steroid-resistant lymphocytes by inhibiting costimulation through CD137. METHODS: Isolated peripheral blood mononuclear cells from transplant patients with stable lung function, patients with BOS, and healthy controls were stimulated with anti-CD3 with and without blocking anti-CD137 and with and without 10(-6) mol/liter methylprednisolone (MP) (with and without stimulatory anti-CD137). Pro-inflammatory cytokine profiles and expression of the cytotoxic mediator, granzyme B, by CD28null T and NKT-like cells were determined using flow cytometry. RESULTS: There was a significant decrease in the percentage of CD28null T and NKT-like cells producing interferon (IFN)-γ, tumor necrosis factor (TNF)-α, and granzyme B in all individuals in the presence of anti-CD137 blocking antibody compared with anti-CD3 alone (eg, 30% decrease in CD8+CD28null TNF-α+ cells). Stimulatory anti-CD137 was associated with an increase in pro-inflammatory/cytotoxic cells. Treatment with anti-CD137 blocking with prednisolone further reduced IFN-γ, TNF-α, and granzyme B in these cells. CONCLUSIONS: Blocking CD137 expression in CD28null T cells and NKT-like cells is associated with down-regulation of IFN-γ, TNF-α, and granzyme B. Targeting CD137 reduces pro-inflammatory/cytotoxic expression in steroid-resistant CD28null T and NKT-like cells and may have therapeutic implications for patients with BOS.
dc.description.statementofresponsibilityGreg Hodge, Sandra Hodge, Paul N. Reynolds, Mark Holmes
dc.identifier.citationJournal of Heart and Lung Transplantation, 2013; 32(11):1081-1089
dc.identifier.doi10.1016/j.healun.2013.07.017
dc.identifier.issn1053-2498
dc.identifier.issn1557-3117
dc.identifier.orcidHodge, S. [0000-0002-3602-9927] [0000-0002-9401-298X]
dc.identifier.orcidReynolds, P. [0000-0002-2273-1774]
dc.identifier.urihttp://hdl.handle.net/2440/81629
dc.language.isoen
dc.publisherElsevier Science Inc
dc.rightsCrown copyright © 2013
dc.source.urihttps://doi.org/10.1016/j.healun.2013.07.017
dc.subjectblocking CD137
dc.subjectBOS
dc.subjectCD28null T cells
dc.subjectIFN-γ
dc.subjectlung transplant
dc.subjectTNF-α
dc.titleTargeting peripheral blood pro-inflammatory CD28null T cells and natural killer T-like cells by inhibiting CD137 expression: Possible relevance to treatment of bronchiolitis obliterans syndrome
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications